About

NASHCO BIOSCIENCE LIMITED was established in 2025 in Northern Ireland and China as an integrated enterprise focusing on the R&D, production, and marketing of pet pharmaceutical health products and medical devices.

Specializing in the field of pet pharmaceutical health products and medical devices, NASHCO ANIMAL HEALTH consistently upholds the corporate value of “Professionally safeguarding the health of pets worldwide and building a harmonious world of human-pet companionship.” The company is dedicated to developing specialized novel pet medications and healthcare products in areas such as anti-infection, dermatology, analgesia, urology, ophthalmology, cardiovascular diseases, and internal/external parasite control.

To support its growth, NASHCO ANIMAL HEALTH has established a global R&D center, an international cGMP-standard factory, and an international marketing center. It possesses professional capabilities in drug dosage design, formulation screening, method validation, pilot-scale amplification, and commercial production in compliance with VICH guidelines, offering CRO/CMO/licensing international services. Its products have achieved GMP certifications in multiple countries and are marketed in five overseas countries.